Poolbeg Pharma US infectious diseases expert, Professor Daniel Hoft, joins Scientific Advisory Board

Poolbeg Pharma plc (LON:POLB) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has appointed Professor Daniel Hoft to its Scientific Advisory Board.

Prof Hoft, M.D., Ph.D. is the Dianna and J. Joseph Adorjan Endowed Chair of Infectious Diseases and Immunology, and Director of the Division of Infectious Diseases, Allergy & Immunology at Saint Louis University (SLU) School of Medicine. He has been working in immunology and infectious diseases for 32 years. Prof Hoft has published over 140 peer reviewed scientific publications.

Prof Hoft will join the Scientific Advisory Board alongside Dr Elaine Sullivan and Prof Luke O’Neill and with his extensive background in infectious disease, immunology, and vaccinology, will guide the Company on its asset development programmes. Prof Hoft will also work with the Company to scout for prospective in-licencing opportunities.

Prof Hoft is heavily involved in vaccine development research, especially for pandemic influenza and tuberculosis which has seen him undertake pioneering work in T-cell targeting vaccines which is particularly relevant to the Company’s Vaccine Discovery Platform. He is Principal Investigator of the SLU’s Vaccine & Treatment Evaluation Unit (VTEU), one of ten US National Institutes of Health (NIH) centers, placing it among an elite group of top academic centers conducting clinical trials of novel vaccines for global protection against future pandemic challenges. Since the SARS-CoV-2 pandemic the SLU VTEU led by Prof Hoft has featured prominently in the urgent COVID-19 vaccine development and Prof Hoft is the VTEU protocol chair for a first-in-human phase I trial of a novel COVID-19 vaccine. He has received numerous awards from NIH, US Department of Defense, and the Bill & Melinda Gates Foundation and is a regular advisor to the World Health Organisation.You might also enjoy reading  Poolbeg Pharma Rapidly progressing towards LPS challenge study

Read Prof Hoft’s full bio on Poolbeg’s website.

Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said: “Prof Hoft is a great addition to the Poolbeg Scientific Advisory Board, joining Dr Elaine Sullivan and Prof Luke O’Neill. His expertise in infectious disease, particularly with severe influenza and vaccine development will be invaluable as we develop Poolbeg’s pipeline of assets. He will also work with the Company to scout for prospective assets to in-licence and develop. Prof Hoft is a widely respected specialist within our industry and we look forward to working with him as we continue our growth journey.” 

Prof Daniel Hoft, M.D., Ph.D., commented:

“Poolbeg has an interesting portfolio of assets within infectious disease with an exciting lead asset, POLB 001. Coupled with its unique access to 20 years’ of human viral challenge study data, means its approach has real potential in this space. I look forward to helping support the business as it develops.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Poolbeg Pharma

More articles like this

Poolbeg Pharma

Poolbeg Pharma partners with Nasdaq-listed biopharma company

Poolbeg Pharma has partnered with a Nasdaq-listed biopharma company on its oral delivery platform. The strategic collaboration will see both companies develop an optimised oral drug to treat a metabolic condition. Poolbeg said that it will

Poolbeg Pharma

The role AI can play in pharmaceutical discovery

The pharmaceutical industry has long been at the forefront of scientific innovation, driving advancements in medicine that aim to improve the quality of human health and lifespan. The race to develop vaccines and treatments for COVID-19

Poolbeg Pharma

Hybridan & Poolbeg Pharma discussion on AI Programs

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Poolbeg Pharma

Revolutionising healthcare: How AI is changing the game

In the swirling world of technological innovation, Artificial Intelligence has carved out a distinctive niche. It’s causing ripples of change across multiple sectors, but perhaps none more so than healthcare. From groundbreaking diagnostics to the fine

Poolbeg Pharma

The growing role of AI in drug discovery

Bringing a new drug to market is an enormously complex and expensive process, often taking over a decade and costing upwards of $2 billion. The pharmaceutical industry faces increasing pressure to improve R&D productivity and efficiency.

Poolbeg Pharma

Poolbeg Pharma gets go-ahead for Japanese patent

Dublin-based infectious disease specialist Poolbeg Pharma has received a green light from Japan’s patent office, relating to a patent application for the company’s “potential blockbuster treatment” for severe influenza. The Japanese Patent Office has issued a

Poolbeg Pharma

AI Unleashed: Experts from Poolbeg Pharma & CytoReason

Roundtable discussion featuring Artificial Intelligence hot topics, such as: The future of AI How AI could have contributed to the COVID-19 pandemic Highlights from the exciting collaboration between Poolbeg Pharma and CytoReason. Speakers: Jeremy Skillington –

Poolbeg Pharma

Poolbeg Pharma plc granted allowance from the Japanese Patent Office

Poolbeg Pharma Plc (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that it has received a notice of allowance from the Japanese Patent Office in relation to its Immunomodulator I patent

Poolbeg Pharma

Poolbeg Pharma patent opposition to be withdrawn

Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that the opposition to one of its European patents (Immunomodulator I) that was previously filed by a third party is

Poolbeg Pharma

AI to revolutionise drug development by 2026

Initial data from the CPHI Annual Report 2023, which provides insight from 250 global pharmaceutical companies, reveals that AI (artificial intelligence) is expected to transform every area of the industry, from drug discovery through to drug development,

Poolbeg Pharma

Poolbeg Pharma make significant progress in advancing pipeline

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced its unaudited interim results for the six months to 30 June 2023. Interim Results Highlights and Business Update ·    Strong

Poolbeg Pharma

Poolbeg Pharma’s Oral Vaccine Platform

By delivering vaccines to the gut, oral vaccines can trigger ‘mucosal immunity’ which prevents pathogens infecting the body by producing a protective response in the areas of the body where there is a high level of

Poolbeg Pharma

Poolbeg Pharma A.I. Unlocking the power of unique human challenge trial data

Poolbeg Pharma (LON:POLB) Chief Executive Officer Jeremy Skillington talks us through the Poolbeg September 2023 company presentation. Poolbeg Pharma (LON:POLB, OTCQB: POLBF), is a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical